CMS decision on NGS coverage is a big step forward for patients and laboratories

By Jeff Schreier, Senior Director, Marketing and Robert Feeney, Marketing Director, Global Lab Relations, Diaceutics.  A hurdle has just been cleared for patients and the laboratories who serve them. On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that covers diagnostic laboratory tests using Next Generation Sequencing (NGS) for […]

CAR T-cell therapy: the cost and payment code conundrum

CAR T-cell therapy is making headlines, mainly for being a groundbreaking and life-saving approach to treat particular types of cancer and rare diseases, including childhood leukemia, but also for its very high price tag. CAR T-cell therapy (chimeric antigen receptor) extracts a patient’s immune cells, genetically engineers them to fight cancer cells, and then reintroduces […]

Diaceutics, Intel and Lenovo advance patient care using AI and workstations powered by Intel® Xeon® Scalable processors

Collaboration will help to organize and categorize patient testing data using artificial intelligence It is a revolutionary method which could help to identify new patient subsets The aim is to further improve the diagnosis and treatment of patients Since it was established, Diaceutics has focused on removing barriers to diagnostic test adoption and plans to […]